Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

March 2022 | 73 pages | ID: A195ED0EF980EN
Global Markets Direct

Abstracts

Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape.

Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. Symptoms include vomiting, abdominal pain, pale skin tone, fatigue and irritability, blood in the urine and confusion.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atypical Hemolytic Uremic Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 1, 3 and 8 respectively.

Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Atypical Hemolytic Uremic Syndrome (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Atypical Hemolytic Uremic Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Atypical Hemolytic Uremic Syndrome (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Atypical Hemolytic Uremic Syndrome (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Overview
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Companies Involved in Therapeutics Development
Aevitas Therapeutics Inc
Alexion Pharmaceuticals Inc
ChemoCentryx Inc
Chugai Pharmaceutical Co Ltd
ImmunAbs Inc
ISU ABXIS Co Ltd
Novartis AG
Omeros Corp
Prestige BioPharma Ltd
Ra Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Tasly Biopharmaceuticals Co Ltd
Turgut Ilaclari AS
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Drug Profiles
avacopan - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVTS-001 - Drug Profile
Product Description
Mechanism Of Action
B-20672 - Drug Profile
Product Description
Mechanism Of Action
CPV-101 - Drug Profile
Product Description
Mechanism Of Action
CPV-102 - Drug Profile
Product Description
Mechanism Of Action
crovalimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
danicopan - Drug Profile
Product Description
Mechanism Of Action
History of Events
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
History of Events
eculizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
IM-101 - Drug Profile
Product Description
Mechanism Of Action
iptacopan hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody for Atypical Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
Product Description
Mechanism Of Action
History of Events
narsoplimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
ravulizumab LA - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit MASP2 for Immunology - Drug Profile
Product Description
Mechanism Of Action
zilucoplan - Drug Profile
Product Description
Mechanism Of Action
History of Events
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Discontinued Products
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Product Development Milestones
Featured News & Press Releases
Sep 14, 2021: Eleva reaches industrial production scale and prepares for clinical development of Factor H
May 10, 2021: The Scottish Medicines Consortium accepted Ultomiris for routine use
Mar 16, 2021: Navigo Proteins and Eleva announce successful development of an affinity chromatography resin customized for the efficient purification of human complement-factor H
Jan 06, 2021: Eleva secures up to EUR 60 million to advance a drug candidate, appoints new Board Member
Nov 24, 2020: ISU ABXIS and Russian Pharmasyntez signed ISU305 technology export contract
Nov 04, 2020: Alexion announces upcoming data presentations at the 62nd American Society of Hematology Annual Meeting and Exposition
Oct 12, 2020: Alexion receives FDA approval for new advanced formulation of ULTOMIRIS (ravulizumab-cwvz) with significantly reduced infusion time
Oct 09, 2020: Alexion announces upcoming data presentations at the American Society of Nephrology’s Virtual Kidney Week 2020
Sep 25, 2020: ULTOMIRIS (ravulizumab) receives approval in Japan for atypical hemolytic uremic syndrome (aHUS) in adults and children
Jun 29, 2020: ULTOMIRIS (ravulizumab) receives marketing authorization from European Commission for adults and children with atypical hemolytic uremic syndrome (aHUS)
Jun 24, 2020: Alexion announces phase 3 study of weekly subcutaneous ULTOMIRIS (ravulizumab-cwvz) met primary endpoint
May 14, 2020: Alexion announces upcoming data presentations at the virtual 25th Congress of the European Hematology Association
Oct 18, 2019: Alexion receives FDA approval for ULTOMIRIS (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
Jun 20, 2019: U.S. FDA accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS (ravulizumab-cwvz) under priority review for the treatment of atypical hemolytic uremic syndrome (aHUS)
Jan 28, 2019: Alexion announces positive top-line results from phase 3 study Of ULTOMIRIS (Ravulizumab-Cwvz) in complement inhibitor-naive patients with Atypical Hemolytic Uremic Syndrome (AHUS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Aevitas Therapeutics Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by ChemoCentryx Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by ImmunAbs Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by ISU ABXIS Co Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Novartis AG, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Omeros Corp, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Prestige BioPharma Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Ra Pharmaceuticals Inc, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Samsung Bioepis Co Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Tasly Biopharmaceuticals Co Ltd, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline by Turgut Ilaclari AS, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Dormant Projects, 2022
Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022